Byond

Most digital health startups don’t fail because the problem isn’t real — they fail in the gap between “great demo” and “actually deployed, reimbursed, and adopted at scale.” That’s the gap I help US-based digital health investors close at the upcoming VC Conf. I’m working with founders scaling an AI‑powered digital health platform used by 40+ independent specialty practices with access to ~300,000 patients — a solution that plugs into major EHRs, requires no new clinical FTEs, is built around recurring reimbursed remote encounters, and has already driven 30x MRR growth while standing up to real clinical and economic scrutiny, not just winning pitch competitions. The top 3 problems we solve for digital health investors 🩺 Higher-signal, de-risked deal flow We surface founders who understand clinical workflows, evidence generation, and healthcare GTM — not just “move fast and break things.” 🧭 Real paths through regulation and reimbursement We help teams turn “we’ll figure out FDA and payers later” into concrete regulatory, reimbursement, and commercialization roadmaps you can actually underwrite. 📊 Cleaner data for faster conviction We work with founders to sharpen outcomes, unit economics, and adoption metrics so you can reach conviction faster, with fewer meetings and less noise. Why you should come meet Byond at VC Conf 💠 Connect with digital health founders who think in terms of clinical outcomes, payer fit, and implementation — not just downloads and vanity metrics. 💠 Meet other investors actively deploying into digital health, value-based care, virtual care, AI-enabled workflows, and health IT infrastructure. 💠 Pressure-test your digital health thesis live against what funds, angels, LPs, and family offices are actually backing in this market. All of this happens in one high-signal virtual day instead of months of scattered Zooms and conferences. 💡 If you’re a US-based digital health investor, this is your chance to upgrade your pipeline, sharpen your thesis, and back founders who can actually make it through the healthcare gauntlet. 👇 Conference link is in the comments. If you’re a serious healthtech/digital health GP, angel, VC, family office, foundation, or ecosystem funder ready to turn capital deployment into a real competitive edge, let’s connect. 🤝 ➕ Follow Byond for more practical, investor-focused tips on sourcing, evaluating, and backing founders who can truly scale in healthcare. #VCCONF #DigitalHealth #HealthTech #HealthcareInnovation #VentureCapital #ValueBasedCare #VirtualCare #HealthIT #AIInHealthcare #LPInsights #AngelInvesting #ByondSolutions

Most deep tech and dual-use startups don’t fail because the technology isn’t real — they fail in the gap between “breakthrough science” and “deployable, defensible, revenue-generating systems.” That’s the gap Byond is helping US-based deep tech and dual-use investors close at the upcoming VC Conf. I’m working with founders building a breakthrough wireless platform that works where nothing else does — underwater, underground, and through metal. They’re targeting high-value deployments across Military (submarine-to-surface), diver communications, subsea oil & gas, UUV networking, and ship compartment communications — unlocking a multibillion-dollar “dead zone” market. Their patented system uniquely delivers kilometer-scale range, high data rates, and low latency in one solution, already validated with $9.5M+ in U.S. defense contracts, $4.2M in 2025 revenue, and a deep IP moat. The top 3 problems Byond solves for deep tech & dual-use investors 1️⃣ Higher-signal, de-risked frontier deal flow We help you access founders who understand mission profiles, operational constraints, and commercialization in defense/industrial contexts — not just lab results and buzzwords. 2️⃣ Clearer paths through defense, industrial, and regulatory risk We work with teams to turn vague “DoD / critical infrastructure / export” ambitions into concrete customer pathways, milestones, and risk you can actually underwrite. 3️⃣ Faster conviction on hard tech with less noise We tighten narratives around technical readiness, unit economics, deployment timelines, and IP defensibility so you can say “yes” or “no” faster — with fewer cycles wasted on science projects. Why you should come meet Byond at VC Conf 💠 Meet founders building deployable deep tech and dual-use systems that solve real Military, government, and industrial problems — not just pitch-day theater. 💠 Connect with other investors actively deploying into defense tech, advanced communications, industrial infrastructure, and critical national security applications. 💠 Pressure-test your deep tech and dual-use thesis live against what other funds, angels, LPs, and family offices are actually backing in this cycle. All of this happens in one high-signal virtual day instead of months of scattered Zooms and conferences. 💡 If you’re a US-based deep tech or dual-use investor, this is a chance to upgrade your pipeline, sharpen your thesis, and back founders who can actually ship into demanding, real-world environments. 👇 Conference link is in the comments. ➕ Follow Byond for more practical, investor-focused tips on sourcing, evaluating, and backing frontier founders who can go the distance. #VCCONF #DeepTech #DualUseTech #DefenseTech #NatSec #IndustrialTech #FrontierTech #VentureCapital #FamilyOffice #AngelInvesting #LPInsights #ByondSolutions

Most digital health startups don’t fail because the problem isn’t real — they fail in the gap between “great demo” and “actually deployed, reimbursed, and adopted at scale.” That’s the gap I help US-based digital health investors close at the upcoming VC Conf. I’m working with founders scaling an AI‑powered digital health platform used by 40+ independent specialty practices with access to ~300,000 patients — a solution that plugs into major EHRs, requires no new clinical FTEs, is built around recurring reimbursed remote encounters, and has already driven 30x MRR growth while standing up to real clinical and economic scrutiny, not just winning pitch competitions. The top 3 problems we solve for digital health investors 🩺 Higher-signal, de-risked deal flow We surface founders who understand clinical workflows, evidence generation, and healthcare GTM — not just “move fast and break things.” 🧭 Real paths through regulation and reimbursement We help teams turn “we’ll figure out FDA and payers later” into concrete regulatory, reimbursement, and commercialization roadmaps you can actually underwrite. 📊 Cleaner data for faster conviction We work with founders to sharpen outcomes, unit economics, and adoption metrics so you can reach conviction faster, with fewer meetings and less noise. Why you should come meet Byond at VC Conf 💠 Connect with digital health founders who think in terms of clinical outcomes, payer fit, and implementation — not just downloads and vanity metrics. 💠 Meet other investors actively deploying into digital health, value-based care, virtual care, AI-enabled workflows, and health IT infrastructure. 💠 Pressure-test your digital health thesis live against what funds, angels, LPs, and family offices are actually backing in this market. All of this happens in one high-signal virtual day instead of months of scattered Zooms and conferences. 💡 If you’re a US-based digital health investor, this is your chance to upgrade your pipeline, sharpen your thesis, and back founders who can actually make it through the healthcare gauntlet. 👇 Conference link is in the comments. If you’re a serious healthtech/digital health GP, angel, VC, family office, foundation, or ecosystem funder ready to turn capital deployment into a real competitive edge, let’s connect. 🤝 ➕ Follow Byond for more practical, investor-focused tips on sourcing, evaluating, and backing founders who can truly scale in healthcare. #VCCONF #DigitalHealth #HealthTech #HealthcareInnovation #VentureCapital #ValueBasedCare #VirtualCare #HealthIT #AIInHealthcare #LPInsights #AngelInvesting #ByondSolutions

You see the gaps every day — clunky tools, burned‑out teams, patients waiting too long for the right care — but no one ever showed you how to back the innovations that could fix it. 🩺💡 You know medtech and healthtech innovation is needed. What’s less clear is how to support the right founders as a physician. Where do you start❓ Which teams can you trust❓ How do you avoid losing money on ideas that never make it past pilots❓ Truth is most medtech and healthtech startups don’t die because the science is bad. They die in the Valley of Death — the gap between promising prototype and a business investors can underwrite. 🏔️ That’s exactly where physician investors can change the game. Why founders need physician investors 1️⃣ Clinical signal You know which problems are real and painful, not edge cases or “nice‑to‑have.” 2️⃣ Workflow reality You see how care actually happens and can warn founders if their solution won’t survive real‑world use. 3️⃣ Meaningful outcomes You steer teams toward outcomes that matter clinically, not vanity metrics. 4️⃣ Credibility Your name on a cap table signals to payers, systems, and investors that the product is grounded in real practice. 5️⃣ Aligned incentives You help keep patient care, outcomes, and sustainability at the center of decisions. How Byond helps physician investors At Byond, we partner with physician investors who want to support innovation intelligently, not passively. We help you: ✅ Spot high‑potential medtech and healthtech founders solving real problems ✅ Separate meaningful innovation from hype and “nice‑to‑have” tools ✅ Review founder stories, strategy, and traction so you see the real risk ✅ Support portfolio teams so your capital doesn’t stall in the Valley of Death Our goal: Help you become a smart physician investor — directing your capital and expertise to the teams most likely to reach patients and scale impact. 📈 If you’re a physician who wants to learn how to become a smart physician investor and help promising medtech and healthtech innovators avoid the Valley of Death, let’s connect. 🤝 ➕ Follow Byond for practical tips tailored to physician investors who want their capital to actually improve care. 🔔 #PhysicianInvestors #PhysiciansInVenture #MedTech #HealthTech #DigitalHealth #FutureOfMedicine #ValleyOfDeath #Byond

You already underwrite clinical risk every day. Why not help underwrite the right innovation too? 🩺💡 If physicians don’t participate in capital allocation, others will decide which tools show up at your patients' bedside. That’s how you end up being forced to use devices and apps that were clearly not built with clinicians or patients in mind. More physicians are stepping into venture and ownership so they can shape which medtech and healthtech innovations actually reach patients — not just react to whatever appears in the EHR. 🚀 Top reasons physicians should back medtech and healthtech founder teams: 1️⃣ You see root‑cause problems and unmet needs long before the market does. 2️⃣ You can tell which solutions will survive real‑world workflows, not just look good in a pitch deck. 3️⃣ Your involvement signals credibility to health systems, payers, and other investors. 4️⃣ You align incentives between clinical outcomes, patient experience, and sustainable business models. At Byond, we work directly with physician investors to de‑risk the seed‑stage medtech and healthtech deals you care about most. We help you: ✅ Separate clinically meaningful innovation from shiny but low‑impact tech ✅ Protect your time and reputation by screening teams and pressure‑testing their story, strategy, and traction ✅ Turn technically strong but messy opportunities into clear, investor‑ready theses you can champion ✅ Support portfolio teams with product, GTM, and fundraising guidance so your capital doesn’t stall in the Valley of Death 🏔️ In short: we help your capital practice medicine at scale — backing founders who can actually get from prototype to patients. 📈 If you’re a physician investor who wants to back high potential medtech/healthtech teams to avoid the Valley of Death and truly reach patients, connect with me here. 🤝 ➕ Follow Byond for more practical tips on evaluating and supporting medtech and healthtech founders. 🔔 #PhysicianInvestors #PhysicianEntrepreneurs #MedTech #HealthTech #DigitalHealth #VentureCapital #FutureOfMedicine #ValleyOfDeath #Byond

Most MedTech startups don’t die in the lab — they die in the gap between a brilliant device and a believable path through regulation, reimbursement, and adoption at scale. That’s the gap we’re helping US-based MedTech investors close at the upcoming VC Conf. I’m working with founders who’ve launched medical devices that are seeing real market traction — 15x MRR in 12 months — while fitting seamlessly into clinical workflows and boosting recurring reimbursement margins for health systems, not just winning pitch competitions. Top 3 problems we solve for MedTech investors 🧪 De-risked, execution-ready deal flow I help surface teams who understand clinical evidence, trial design, and the realities of getting from prototype to first-in-human and beyond. 🛂 Realistic regulatory and market-access roadmaps I work with founders to turn vague “we’ll handle FDA and go global later” into clear device classification, regulatory pathways, timelines, and gating milestones you can actually underwrite. 💵 Clearer economics and adoption stories I help tighten the narrative around capital intensity, margins, sales cycles, and purchasing dynamics so you can reach conviction faster and avoid wasting cycles on “science projects.” Why you should come meet us at VC Conf: 💠 Meet medtech founders who think beyond the prototype and are designing for trials, approvals, and commercialization from day one. 💠 Connect with other investors actively backing devices, diagnostics, surgical tools, robotics, and hospital infrastructure — not just generic digital health. 💠 Pressure-test your medtech thesis against what other funds, angels, LPs, and family offices are actually funding in this cycle. All in one concentrated, high-signal environment instead of months of scattered Zooms and conference hallway chats. 👇 Conference link is in the comments. If you’re a serious MedTech GP, angel, VC, family office, foundation, or ecosystem funder ready to turn capital deployment into a real competitive edge, let’s connect. ➕ Follow Byond for more practical, investor-focused tips on sourcing, evaluating, and backing founders who can actually ship frontier tech. #VCCONF #DeepTechVC #DualUseTech #FrontierTech #VentureCapital #DefenseTech #IndustrialTech #AIInvesting #InfraTech #LPInsights #AngelInvesting #FamilyOffice #ByondSolutions

Most deep tech breakthroughs die in the gap between “brilliant science” and “backable business” — not because the tech is weak, but because the investor network around it is thin and slow to move. On March 31, you get a rare chance to compress months of intros, conferences, and cold outreach into one high-signal virtual day. I’m currently working with a client set to disrupt the wireless communications market by delivering high-speed, secure signals underwater and through underground pipelines — exactly the kind of frontier problem set this event is built for. Why deep tech investors should care If you’re a US-based deep tech, dual-use, or frontier tech investor, you’re likely facing: 💠 Deal flow that’s too generic or not technical enough. 💠 Syndicates that don’t understand long R&D cycles or regulatory drag. 💠 Founders who can build frontier tech but can’t structure capital-efficient, milestone-driven rounds. This event is designed to directly attack those problems. What you get in one day: ✅ 6+ hours of content showing how top funds are actually underwriting risk and structuring rounds in 2026. ✅ 30+ speakers across VCs, angels, LPs, and family offices sharing what’s working right now. ✅ 70+ Zoom breakout rooms hosted by 170+ active investors so you can quickly find people who truly “get” deep tech, dual-use, and industrial innovation. ✅ A session with Foundersuite CEO Nathan Beckord on “Going International Day 1” — ideal for cross-border deep tech and defense plays that must be global from the start. All upside. Zero ticket cost. Zero travel friction. The invite 🔹 Event: Virtual VC Conf (for investors and startups) 🔹 Date: March 31, 2026 🔹 Format: Free, fully virtual on Zoom with structured breakout rooms If you’re a serious investor (GP) or funder (Fund Manager) ready to turn capital deployment into US-based deep tech, dual-use, industrial, or frontier tech a real competitive advantage, let's connect. 👇 Conference link is in the comments. ➕ Follow Byond for more actionable tips for investors on sourcing, evaluating, and backing deep tech founders who can actually ship. #VCCONF #DeepTechVC #DualUseTech #FrontierTech #VentureCapital #DefenseTech #IndustrialTech #AIInvesting #LPInsights #FamilyOffice #AngelInvesting #ByondSolutions

Some of the most painful losses in medtech aren’t bad picks. They’re good picks funded on the wrong timeline. 📉 You’ve probably seen this story: A strong team hits proof of concept, nails early clinical signals, and raises a respectable Series A. The model assumes a “standard” 510(k)/PMA path and a neat step‑up into Series B. Then the hidden tax shows up: rework after design freeze, documentation drag, deficiencies, 180‑day holds. Regulatory time quietly stretches 30–50%. Burn follows. Capital stack wasn’t built for that world. The company limps into toxic bridges, terms spiral, and eventually a clinically valuable asset dies pre‑market. This isn’t just undercapitalization. It’s mis‑capitalization against regulatory reality. The outliers who survive — and return — look different: ✅ Their founders treat regulatory strategy as a first‑order driver of survival and valuation, not a cost center. ✅ They front‑load classification, standards, and requirements to avoid “loop‑back” and budget‑eating rework. ✅ They institutionalize documentation and quality early instead of letting engineers drown at the end. ✅ They approach submissions assuming holds and questions, with systems to respond fast and clean. Most importantly: they raise and structure capital around that reality — aligning non‑dilutive, specialist, and long‑horizon investors with each regulatory gate. You can’t move the FDA clocks. You can choose to back teams who design for those clocks — and underwrite a capital plan that survives when the happy path breaks. At Byond, we partner with medtech founders to architect capital stacks and execution plans that anticipate regulatory drag, not ignore it — so investors’ best companies don’t stall in the valley of death. If you’re serious about compounding returns in medtech, follow Byond for more investor‑oriented insights on capital design, regulatory timing, and portfolio durability. 📈 #medtech #VC #healthtech #FDA #venturecapital #capitalstack #startupinvesting

Listening to the “Funding Your Innovation” panel at the 2026 Maryland Medtech Summit, I heard what many investors really think about medtech founders: visionary, mission-driven, technically brilliant… and often unprepared for the brutal valley of death between seed funding and sustainable revenue. ⛰️💉 I left inspired by their honesty — and disappointed that almost no one talked about the valley of death, where most medtech teams actually fail. That silence matters, because you can’t manage a risk you never name. According to experts, here are the top 3 reasons most medtech teams get stuck in the valley of death: 1️⃣ Underestimating true capital needs Teams raise enough for prototypes or a small study, but not enough to navigate regulatory, clinical validation, and early commercialization. They hit the wall just as things get real. 2️⃣ Weak reimbursement and adoption strategy Founders optimize for FDA, but don’t build a parallel plan for coding, coverage, payment, and health system integration. Without revenue logic, even approved tech struggles to scale. 3️⃣ No integrated roadmap across science, regulation, and business Brilliant tech; fragmented plan. Regulatory, clinical, commercial, and fundraising workstreams aren’t aligned to milestones, so time and capital get burned without clear value inflection. This is exactly where Byond steps in for medtech founders. At Byond, we work with medtech teams to avoid the valley of death by helping you: ☑️ Build a realistic capital and milestone roadmap from prototype to FDA, reimbursement, and system-wide adoption. ☑️ Integrate regulatory, clinical, and go‑to‑market strategies so every round funds real risk reduction. ☑️ Translate your innovation into investor-ready narratives that resonate with angels, VCs, foundations, and strategic partners. You shouldn’t have to choose between impact and investability. The right structure lets you have both: safer, more effective solutions for patients and stronger, more resilient medtech companies for Maryland and beyond. 🏥🚀 If you’re a medtech founder who wants to design your company to cross the valley of death — not fall into it — let’s connect. 💬 #MarylandMedTech #MedTechSummit #MedTechWeek #MedTechFounders #MedTechStartups #ValleyOfDeath #FundingStrategy #GoToMarket #RegulatoryStrategy #Reimbursement #HealthInnovation #HealthSystems

Most investors on the “Funding Your Innovation” panel at the 2026 Maryland Medtech Summit spoke about valuations, milestones, and markets — but not about the brutal reality that most medtech teams die in the valley of death between seed and real revenue. ⛰️💉 Sitting in the room, I was both energized and disappointed. Energized by the caliber of investors on stage. Disappointed that almost no one named why so many promising Maryland medtech teams never make it out of that dangerous middle. From experts and data, the top 3 reasons most medtech teams get stuck in the valley of death: 1️⃣ Under-capitalized regulatory and clinical path They raise enough for prototypes and early data, but not enough to cross the full FDA, clinical validation, and early commercialization gap. Cash runs out just as risk is finally being retired. 2️⃣ No credible reimbursement and adoption plan Teams treat reimbursement and health system integration as “later” problems. Without a clear path to codes, coverage, payment, and workflow fit, even strong technologies stall after approval. 3️⃣ Misalignment with investor expectations and timing Founders and investors don’t share a realistic 7–10 year view on milestones, dilution, and capital intensity. Boards push for “software timelines” in a hardware + clinical + regulatory world. If we want Maryland to be a true medtech hub, capital strategy has to be part of the solution, not part of the problem. That’s where Byond comes in. At Byond, we work with medtech investors to boost the performance of their portfolio companies by: ✅ Stress-testing regulatory, reimbursement, and integration roadmaps before major checks are written. ✅ Helping founders translate science and clinical promise into investable milestones and capital plans. ✅ Identifying where targeted capital and strategic support can pull teams out of the valley of death faster, with less waste. When investors and advisors align around a realistic, milestone-based journey, more medtech teams survive, more patients benefit, and more funds see real exits — not just write-offs. 📈 If you’re a serious MedTech GP, angel, VC, family office, foundation, or ecosystem funder ready to turn capital deployment into a real competitive edge, let’s connect. #MarylandMedTech #MedTechSummit #MedTechWeek #MedTechInvestors #MedTechFunding #ValleyOfDeath #VentureCapital #ImpactInvesting #FamilyOffice #HealthInnovation #HealthSystems #ValueBasedCare